Influence of heterogeneous age-group contact patterns on critical vaccination rates for herd immunity to SARS-CoV-2.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 02 2022
16 02 2022
Historique:
received:
27
08
2021
accepted:
30
01
2022
entrez:
17
2
2022
pubmed:
18
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Currently, several western countries have more than half of their population fully vaccinated against COVID-19. At the same time, some of them are experiencing a fourth or even a fifth wave of cases, most of them concentrated in sectors of the populations whose vaccination coverage is lower than the average. So, the initial scenario of vaccine prioritization has given way to a new one where achieving herd immunity is the primary concern. Using an age-structured vaccination model with waning immunity, we show that, under a limited supply of vaccines, a vaccination strategy based on minimizing the basic reproduction number allows for the deployment of a number of vaccine doses lower than the one required for maximizing the vaccination coverage. Such minimization is achieved by giving greater protection to those age groups that, for a given social contact pattern, have smaller fractions of susceptible individuals at the endemic equilibrium without vaccination, that is, to those groups that are more vulnerable to infection.
Identifiants
pubmed: 35173229
doi: 10.1038/s41598-022-06477-0
pii: 10.1038/s41598-022-06477-0
pmc: PMC8850460
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2640Subventions
Organisme : National Science Foundation (NSF)
ID : IIS-2027336
Informations de copyright
© 2022. The Author(s).
Références
Science. 2020 Aug 14;369(6505):846-849
pubmed: 32576668
BMJ Open. 2020 Aug 5;10(8):e039856
pubmed: 32759252
Am J Epidemiol. 2005 Feb 15;161(4):303-6
pubmed: 15692073
Math Biosci. 2004 Sep;191(1):19-40
pubmed: 15312742
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25897-25903
pubmed: 32963094
Science. 2021 Feb 26;371(6532):916-921
pubmed: 33479118
Nat Rev Immunol. 2021 Jun;21(6):395-404
pubmed: 33927374
J Theor Biol. 2022 May 7;540:111063
pubmed: 35189135
J Infect. 2015 Jun;71 Suppl 1:S112-20
pubmed: 25934325
J R Soc Interface. 2011 May 6;8(58):661-70
pubmed: 20943682
Epidemics. 2011 Sep;3(3-4):143-51
pubmed: 22094337
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252
Epidemiology. 2019 Sep;30(5):723-736
pubmed: 31274572
Lancet Microbe. 2021 Dec;2(12):e666-e675
pubmed: 34632431
Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):
pubmed: 33632802
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Science. 1982 Feb 26;215(4536):1053-60
pubmed: 7063839
BMC Res Notes. 2020 Jun 16;13(1):293
pubmed: 32546245
Proc Natl Acad Sci U S A. 2021 May 25;118(21):
pubmed: 34011611
Nature. 2021 Mar;591(7851):520-522
pubmed: 33737753
Front Physiol. 2021 Jan 12;11:571416
pubmed: 33510644
Lancet. 2020 Nov 21;396(10263):1614-1616
pubmed: 33159850
J R Soc Interface. 2010 Jun 6;7(47):873-85
pubmed: 19892718
PLoS One. 2015 Mar 03;10(3):e0118457
pubmed: 25734772
J Immunoassay Immunochem. 2020 Nov 1;41(6):928-945
pubmed: 33086932
Sci Rep. 2021 Mar 23;11(1):6626
pubmed: 33758218
Epidemics. 2012 Jun;4(2):78-85
pubmed: 22664066
Vaccine. 2020 Dec 14;38(52):8264-8272
pubmed: 33229108